Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.

For more information on how to use this blog
click here, the HCV drug pipeline click here, and for more information on HCV clinical trials click here

Be sure to check out our other blogs: The HBV Advocate Blog and Hepatitis & Tattoos.

Alan Franciscus
Editor-in-Chief
HCV Advocate
HBV Advocate

Tuesday, August 16, 2011

Use of New HCV Protease Inhibitors ‘Not That Simple’

On May 13, patients began phoning Donald Jensen, MD, at his office at the University of Chicago’s Center for Liver Diseases, as soon as the FDA announced its approval of boceprevir. The call frequency increased when the FDA gave the go-ahead for telaprevir several days later.

Within two weeks, more than 115 patients had phoned the office asking about the much-anticipated, direct-acting antivirals. Patients wanted to know if they were candidates for one of the new agents and if they could trade their pegylated interferon and ribavirin regimen for one of the new therapies. And, most often, they wanted to know when they could start.

Read more.....

No comments:

Post a Comment